Case Report: Acral MYH10::ALK fusion superficial mesenchymal neoplasm: first proof of metastatic potential - Takeaways - MDSpire

Case Report: Acral MYH10::ALK fusion superficial mesenchymal neoplasm: first proof of metastatic potential

  • By

  • Masih Kameh Khosh

  • Sascha Wellenbrock

  • Daniel Kameh Khosh

  • Tobias Hirsch

  • Abbas Agaimy

  • Dan Mon O'Dey

  • June 2, 2026

  • 0 min

Share

  • 1

    A 23-year-old male presented with a purplish mass on the left foot, which enlarged over one year and was diagnosed as an ALK-rearranged tumor.

  • 2

    Histopathology revealed increased mitotic activity and a MYH10::ALK fusion, indicating potential for aggressive behavior despite typical indolence.

  • 3

    Initial surgical excision showed positive margins, and a subsequent re-excision revealed residual tumor, which the patient declined to remove.

  • 4

    The patient developed metastatic disease during follow-up, highlighting the metastatic potential of ALK-rearranged mesenchymal tumors.

  • 5

    This case contributes to understanding the behavior of acral ALK-rearranged tumors and emphasizes the need for thorough clinical management.

Original Source(s)

Case Report: Acral MYH10::ALK fusion superficial mesenchymal neoplasm: first proof of metastatic potential

  • by Masih Kameh Khosh, Sascha Wellenbrock, Daniel Kameh Khosh, Tobias Hirsch, Abbas Agaimy, Dan Mon O'Dey

  • June 2, 2026

Related Content

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

Application of patient-derived organotypic tumor spheroids to guide combination immunotherapy for advanced HCC: a case report

The trinity of T cell engagement: navigating the molecular and clinical landscape of CAR-T, TILs, and TCEs in the war against cancer